Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan.
Share
Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies.
'Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for small to mid-size biotech, Novotech leverages deep therapeutic expertise and regional agility to deliver speed, flexibility, and transformative impact in clinical trials.'
— Unmesh Lal, Vice President – Healthcare & Life Sciences, Frost & Sullivan
According to Frost & Sullivan, Novotech's client-first approach, coupled with its scale and scientific capabilities, continues to set it apart in the biotech CRO space. The firm's deep therapeutic expertise in oncology, rare diseases, infectious diseases, and advanced modalities—such as gene therapies and RNA-based treatments—was cited as a key differentiator.
The award also acknowledged Novotech's ability to maintain trial continuity and delivery excellence amid geopolitical, operational, and economic volatility. Strategic use of AI-enabled tools, predictive analytics, and real-time data platforms further enables Novotech to accelerate timelines and improve decision-making for biotech sponsors.
'We're honored by Frost & Sullivan's recognition, which highlights Novotech's strategic focus on delivering regional expertise through a global model to support biotech and mid-size pharma sponsors. It also reflects the strength of our teams in driving operational, scientific, and client delivery excellence worldwide.'
— Dr. John Moller, CEO, Novotech
Unmesh Lal added: 'Frost & Sullivan believes Novotech's road ahead is about growing without losing its soul: scaling globally while staying deeply connected to biotech clients, preserving its cultural DNA, and delivering the high-touch, high-value service that has become its hallmark.'
The award was accepted on behalf of Novotech by Scott Schliebner, Vice President of Drug Development Consulting, during the Frost & Sullivan Excellence in Best Practices Awards Gala held in Los Angeles, California, on June 26.
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide.
Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
For more information or to speak to an expert team member visit www.Novotech-CRO.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Sugar Prices Recover on Possible Frost Risk in Brazil
October NY world sugar #11 (SBV25) today is up +0.75 (+4.81%), and August London ICE white sugar #5 (SWQ25) is up +19.40 (+4.23). Oct NY sugar today matched Wednesday's contract low but then rallied sharply on short-covering sparked a frost scare in Brazil. The NY sugar nearest-futures July contract posted a 4.25-year low on Monday. Aug London sugar today rallied sharply from Wednesday's 3.75-year nearest-futures low. Arabica Coffee Prices Are Falling. How Much Lower Will They Go? Brazil Coffee Harvest Pressures Weigh on Prices Coffee Prices Fall as Pace of Brazil's Coffee Harvest Accelerates Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Sugar prices rallied sharply today as forecasts indicate a possible frost event in Brazil later this month. The peak time for frost in Brazil's sugar-growing areas is late July through early-August. Sugar prices have plummeted over the past three months due to expectations of a global sugar surplus. On Monday, commodities trader Czarnikow projected a 7.5 MMT global sugar surplus for the 2025/26 season, the largest surplus in 8 years. On May 22, the USDA, in its biannual report, projected that global 2025/26 sugar production would increase by +4.7% y/y to a record 189.318 million metric tons (MMT), with global sugar ending stocks at 41.188 MMT, up 7.5% year-over-year. The outlook for higher sugar production in India, the world's second-largest producer, is bearish for prices. On June 2, India's National Federation of Cooperative Sugar Factories projected that India's 2025/26 sugar production would climb +19% y/y to 35 MMT, citing larger planted cane acreage. The outlook for abundant rainfall in India could lead to a bumper sugar crop, which is bearish for prices. On April 15, India's Ministry of Earth Sciences projected an above-normal monsoon this year, with total rainfall forecast to be 105% of the long-term average. India's monsoon season runs from June through September. Signs of larger global sugar output are negative for prices. On May 22, the USDA's Foreign Agricultural Service (FAS) predicted that Brazil's 2025/26 sugar production would rise +2.3% y/y to a record 44.7 MMT. Also, India's 2025/26 sugar production is projected to rise +25% y/y to 35.3 MMT, citing favorable monsoon rains and increased sugar acreage. In addition, Thailand's 2025/26 sugar production is expected to climb +2% y/y to 10.3 MMT. In a bearish factor, the Indian government said on January 20 that it would allow its sugar mills to export 1 MMT of sugar this season, easing the restrictions placed on sugar exports in 2023. India has restricted sugar exports since October 2023 to maintain adequate domestic supplies. India allowed mills to export only 6.1 MMT of sugar during the 2022/23 season to September 30, after allowing exports of a record 11.1 MMT in the previous season. However, the ISMA projects that India's 2024/25 sugar production will fall -17.5% y/y to a 5-year low of 26.2 MMT. Also, the ISMA reported last Monday that India's sugar production from Oct 1-May 15 was 25.74 MMT, down -17% from the same period last year. In addition, Indian Food Secretary Chopra said on May 1 that India's 2024/25 sugar exports may only total 800,000 MT, below earlier expectations of 1 MMT. The outlook for higher sugar production in Thailand is bearish for sugar prices. On May 2, Thailand's Office of the Cane and Sugar Board reported that Thailand's 2024/25 sugar production rose +14% y/y to 10.00 MMT. Thailand is the world's third-largest sugar producer and the second-largest exporter of sugar. Sugar prices have some support from reduced sugar production in Brazil. Unica reported Monday that the cumulative 2025/26 Brazil Center-South sugar output through mid-June is down by -14.6% y/y to 9.404 MMT. Last month, Conab, Brazil's government crop forecasting agency, said 2024/25 Brazil sugar production fell by -3.4% y/y to 44.118 MMT, citing lower sugarcane yields due to drought and excessive heat. The International Sugar Organization (ISO) raised its 2024/25 global sugar deficit forecast to a 9-year high of -5.47 MMT on May 15, up from a February forecast of -4.88 MMT. This indicates a tightening market following the 2023/24 global sugar surplus of 1.31 MMT. ISO also cut its 2024/25 global sugar production forecast to 174.8 MMT from a February forecast of 175.5 MMT. The USDA, in its bi-annual report released May 22, projected that global 2025/26 sugar production would climb +4.7% y/y to a record 189.318 MMT and that global 2025/26 human sugar consumption would increase +1.4% y/y to a record 177.921 MMT. The USDA also forecasted that 2025/26 global sugar ending stocks would climb +7.5% y/y to 41.188 MMT. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
32 minutes ago
- Business Wire
Hamilton ETFs Announces the Promotion of Jennifer Mersereau and Patrick Sommerville as Co-Chief Executive Officers
TORONTO--(BUSINESS WIRE)--Hamilton Capital Partners Inc. ('Hamilton ETFs') is pleased to announce the promotion of Jennifer Mersereau as Co-Chief Executive Officer and Co-Founder, and Patrick (Pat) Sommerville as Co-Chief Executive Officer, effective July 1, 2025. Appointed in July 2024 as Co-Presidents, Jennifer and Pat bring significant experience to this new role and a shared vision for Hamilton ETFs' continued growth. Jennifer, who co-founded the firm in 2009, has nearly three decades of experience in the financial services sector. Pat joined Hamilton ETFs in 2013 and has over 20 years of experience in wealth management. Together, they have been instrumental in shaping the firm's strategic direction, driving growth, and fostering a strong entrepreneurial, client-focused culture. ' Almost exactly a year ago, Jennifer and Pat were promoted to Co-Presidents and over this period, the firm's performance has been exceptional. Under their leadership – and with the hard work of our amazing team – the firm's AUM increased by 70% in f2025 to over $8.7 billion, driven by record inflows of over $3.0 bln. Over the same period, our product shelf increased by 50% to 30 ETFs with consecutive successful launches driving the firm's excellent growth,' said Robert Wessel, Executive Chairman and Co-Founder of Hamilton ETFs. These leadership promotions mark an important milestone in Hamilton ETFs' continued evolution as it enters its next phase of growth and innovation. New Independent Board Member Hamilton ETFs also announces the recent appointment of Peter Jelley, President and Chief Executive Officer of Bulldog Capital Partners Inc., to its board of directors as an independent board member, effective April 22, 2025. Peter brings insights from more than 25-years in investment banking and private equity and currently serves as Chair of the Board of the Andlauer Healthcare Group, in addition to holding board roles with several private companies. Peter's appointment follows the unexpected passing of Robert Brooks, an original board member of Hamilton Capital Partners Inc., in November 2024. About Hamilton ETFs With over $8 billion in AUM, Hamilton ETFs is one of Canada's fastest growing ETF providers, offering a suite of innovative exchange traded funds (ETFs) designed to maximize income and growth from trusted sectors in Canada and across the globe. The firm is also an active commentator on the global financial services sector and Canadian banks; the firm's most recent Insights can be found at Commissions, management fees and expenses all may be associated with an investment in exchange traded funds (ETFs). Please read the prospectus before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated.
Business Wire
36 minutes ago
- Business Wire
Dominion Energy Schedules Second-Quarter 2025 Earnings Call
RICHMOND, Va.--(BUSINESS WIRE)--Dominion Energy (NYSE: D) will host its second-quarter 2025 earnings call at 10 a.m. ET on Friday, August 1, 2025. Management will discuss matters of interest to financial and other stakeholders including recent financial results. A live webcast of the conference call, including accompanying slides and other financial information, will be available on the investor information pages at For individuals who prefer to join via telephone, domestic callers should dial 1-800-343-5172 and international callers should dial 1-203-518-9856. The conference ID for the telephonic earnings call is DOMINION. Participants should dial in 10 to 15 minutes prior to the scheduled start time. A replay of the webcast will be available on the investor information pages by the end of the day August 1. A telephonic replay of the earnings call will be available beginning at about 1 p.m. ET on August 1. Domestic callers may access the recording by dialing 1-800-839-9409. International callers should dial 1-402-220-6088. The passcode for the replay is 17292. About Dominion Energy Dominion Energy (NYSE: D), headquartered in Richmond, Va., provides regulated electricity service to 3.6 million homes and businesses in Virginia, North Carolina, and South Carolina, and regulated natural gas service to 500,000 customers in South Carolina. The company is one of the nation's leading developers and operators of regulated offshore wind and solar power and the largest producer of carbon-free electricity in New England. The company's mission is to provide the reliable, affordable, and increasingly clean energy that powers its customers every day. Please visit to learn more.
